Genix Pharmaceuticals Corporation (TSXV:GENX)

Market Cap	2.07M
Revenue (ttm)	1.07K
Net Income (ttm)	-87.43K
Shares Out	59.22M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,300
Average Volume	2,565
Open	0.0400
Previous Close	0.0400
Day's Range	0.0400 - 0.0400
52-Week Range	0.0300 - 0.0900
Beta	0.47
RSI	57.71
Earnings Date	Jun 26, 2025

About Genix Pharmaceuticals

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults. It also markets and sells nutraceuticals and pharmaceutical products, su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,000
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: GENX

Financial Performance

In 2024, Genix Pharmaceuticals's revenue was 4,051, a decrease of -67.19% compared to the previous year's 12,347. Losses were -73,196, -98.33% less than in 2023.